Get the Stockscreener App
28.82
2.46%
0.725
Kiniksa Pharmaceuticals International Plc stock is traded at $28.82, with a volume of 103.28K.
It is up +2.46% in the last 24 hours and up +1.70% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$28.09
Open:
$28.26
24h Volume:
103.28K
Relative Volume:
0.13
Market Cap:
$1.22B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-205.82
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+2.97%
1M Performance:
+1.70%
6M Performance:
+56.92%
1Y Performance:
+35.69%
1-Day Range:
$28.17
$28.92
1-Week Range:
$27.06
$29.25
52-Week Range:
$17.82
$30.69
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
28.81 | 2.04B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
156.24 | 69.92B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.21 | 47.07B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.93 | 45.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 19.32B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
296.65 | 13.10B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Rice Hall James & Associates LLC Has $13.87 Million Stock Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLC - Defense World
KNSA: Analyst Maintains Overweight Rating, Raises Price Target | - GuruFocus
Allspring Global Investments Holdings LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Wealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth - AOL.com
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Peregrine Capital Management LLC Purchases 65,147 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Asset Management One Co. Ltd. Makes New $41,000 Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
AMI Asset Management Corp Has $1.73 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari Sells 17,300 Shares - MarketBeat
Kiniksa pharma COO Tessari sells $489k in shares By Investing.com - Investing.com India
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha
Lewis & Ellis acquires Huggins Actuarial Services - Yahoo
UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo
Payment software firm Payrails raises $32m in funding - Yahoo
WRAP EU leads textiles extended producer responsibility talks - Yahoo
Canary raises $80m to fuel expansion in hospitality AI - Yahoo
FirmaPak expands global footprint with Lighthouse Packaging acquisition - Yahoo
FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo
Israel attacks Iran, stock market futures tumble - Yahoo
Green Bay Packaging Executive Vice President Bryan Hollenbach to retire in August - Yahoo
Jio BlackRock gets nod to operate as investment adviser in India - Yahoo
Output of key food commodities “on course for new records” – FAO - Yahoo
Why Oklo Stock Dropped on Thursday - Yahoo
Medtech leaders unite on Capitol Hill to fight tariffs - Yahoo
Actabl launches new ProfitSword digital night audit feature for hotels - Yahoo
UCC Holding and Ashghal launch 3D Printed Schools Project in Qatar - Yahoo
Grant Thornton Advisors appoints new COO - Yahoo
Biggby Coffee unveils first brand refresh - Yahoo
Prime Drink Group’s bottling unit enters receivership - Yahoo
Del Taco expands to Louisville with new franchise agreement - Yahoo
Trump’s Treasury Sec Admits It’s Another TACO Day With China - Yahoo
Hakkers and Paebbl introduce carbon-storing solution at Port of Rotterdam - Yahoo
Mistral unveils Europe’s first AI reasoning model Magistral - Yahoo
Costco Announces Important Change for Certain Members Starting June 30 - Yahoo
Transcript : Kiniksa Pharmaceuticals International, plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
MSD receives FDA approval for Enflonsia to prevent RSV - Yahoo
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
KNSA stock soars to 52-week high, hits $29.71 amid robust gains - Investing.com UK
Kiniksa sets Phase 2/3 trial for heart drug KPL-387 - Investing.com Nigeria
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | K - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis - marketscreener.com
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | KNSA Stock News - GuruFocus
Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | KNSA Stock News - GuruFocus
Kiniksa Pharmaceuticals Announces Trial Design of Planned - GlobeNewswire
Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released - Stock Titan
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis - The Manila Times
Louis Vuitton files lawsuit against Portuguese liqueur start-up over branding rights - Yahoo
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions - TipRanks
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tessari Eben | CHIEF OPERATING OFFICER |
Jun 16 '25 |
Sale |
28.28 |
17,300 |
489,244 |
61,563 |
1.43%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):